Primary market research and patient segmentation mapping in myelofibrosis

Challenge: A venture-backed US biotech company was developing a preclinical biologic for haematological indications and wished to quantify the commercial opportunity for the product in treating...
Learn More

Developing a revenue model for an AI application for GI Imaging

Challenge: Our client was a medical solutions provider specialising in AI applications applied to real-time analysis of medical imagery to provide clinicians with real-time decision-making...
Learn More

Validating the opportunity for a novel anticoagulant with KOL research

Challenge: A research-focused biotech company developing a novel, first-in-class, next generation oral anticoagulant for the prevention of life-threatening thrombotic events asked Alacrita to...
Learn More

EU value proposition and market access plan for orphan disease drug

Challenge: A Swiss biopharma company was developing a therapeutic for a severe orphan disorder. The company had successfully obtained Breakthrough Therapy Designation by the FDA and PRIME status by...
Learn More

Strategic positioning guidance for Rx microbiome product

Challenge: A company with a microbiome-conditioning product was seeking the optimum strategic positioning to enable a trade sale to a major company. Unusually for a venture in this field, the company...
Learn More

Providing expert due diligence for the reformulation of a marketed biologic

Challenge An established European pharma company needed an opportunity assessment for a reformulation of a marketed biologic.
Learn More

Value proposition and pricing for novel GI treatment

Challenge: A clinical stage pharma company with development and commercialization rights to a novel treatment for GI indications wanted to gain marketing authorization in Europe. However, the...
Learn More

European market access support for clinical stage biopharma company

Challenge: A clinical stage biopharma company developing a novel small molecule to treat a rare respiratory disorder had conducted an Advisory Board to finalize the design of later stage clinical...
Learn More

Market landscape exercise for three oncology therapeutics

Challenge A leading private US academic institution, recognizing the need to further develop early discoveries from the university in order to facilitate industry partnerships and clinical...
Learn More

European Payer value requirements in GAD

Challenge A privately held specialty pharmaceutical company focused in the field of psychiatry was conducting a Phase III clinical evaluation of its new formulation (one-per-day) of a commonly...
Learn More

Market opportunity for colistin potentiators

Challenge A Spanish university spinout with an integrated platform to discover and develop new antimicrobials and adjuvants with novel mechanisms of action, was advancing a potentiator program that...
Learn More

Providing high-level gap analysis of European market access

Challenge A US venture-funded biotech was planning a pivotal trial with a highly efficacious infectious disease therapy. It asked Alacrita’s pharma market access consultants to conduct a high-level...
Learn More
1 2